Welcome to our dedicated page for Entrada Therapeutics SEC filings (Ticker: TRDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Entrada Therapeutics, Inc. (Nasdaq: TRDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Entrada is a clinical-stage biopharmaceutical company developing RNA- and protein-based therapeutics using its Endosomal Escape Vehicle (EEV™) technology for neuromuscular, ocular and other diseases.
For TRDA, key filings include periodic reports and current reports on Form 8-K. Recent Form 8-K filings furnished by Entrada cover quarterly financial results and corporate updates, such as results for the quarters ended June 30, 2025 and September 30, 2025. These filings confirm that Entrada’s common stock is registered on The Nasdaq Global Market under the symbol TRDA and identify the company as an emerging growth company.
Through this page, users can review how Entrada reports on its financial condition, collaboration revenue, research and development expenses, and other operating metrics in documents that are incorporated by reference into its SEC record. While the detailed content of annual reports on Form 10-K, quarterly reports on Form 10-Q and proxy statements is not reproduced here, this filings hub is the starting point for locating those documents on EDGAR.
Stock Titan enhances access to Entrada’s SEC filings by organizing them chronologically and highlighting document types that matter to investors, such as Forms 8-K, 10-K, 10-Q and, when applicable, insider transaction reports on Form 4. AI-driven tools can help summarize lengthy filings and clarify technical language, allowing readers to more quickly understand how Entrada describes its EEV platform, clinical programs and financial results in its official regulatory disclosures.
Sethuraman Natarajan, an officer at Entrada Therapeutics, Inc. (TRDA), reported a sale of 1,760 shares of the company's common stock on 09/02/2025 to satisfy tax withholding obligations from vested restricted stock units. The filing shows a weighted-average sale price of $5.4302, with individual trade prices ranging from $5.36 to $5.58. After the reported disposition, the reporting person beneficially owns 197,899 shares. The Form 4 was signed by an attorney-in-fact on 09/04/2025. The filing is a routine insider report documenting a tax-withholding sale tied to RSU vesting and does not state any other transactions or derivative holdings.
Entrada Therapeutics CFO Kory James sold 1,734 shares on 09/02/2025 to cover tax withholding arising from RSU vesting. The weighted-average price for the sales was $5.4302, with transaction prices reported between $5.36 and $5.58. After the sale, the reporting person beneficially owned 118,936 shares, held directly. The Form 4 was filed indicating the sale was to satisfy withholding obligations tied to previously granted restricted stock units.
Janus Henderson Group plc reports beneficial ownership of 1,521,281 shares of Entrada Therapeutics common stock, representing 4.0% of the class. The filing states Janus Henderson has no sole voting or dispositive power and shared voting and dispositive power over all reported shares.
The filing identifies certain indirect subsidiaries (including JHIUS, JHIUKL and JHIAIFML) as registered investment advisers furnishing advice to Managed Portfolios and includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Entrada Therapeutics, Inc. (Form 10-Q) — quarter ended June 30, 2025. The company reported $72.5M cash and cash equivalents and $281.5M marketable securities (total $354.0M) and total assets of $448.8M as of June 30, 2025. Total liabilities were $69.3M and accumulated deficit was $189.8M. Shares outstanding: 38,033,970 as of June 30, 2025 (38,037,079 as of July 31, 2025).
Operational and financial results: collaboration revenue was $1.95M for Q2 2025 and $22.51M for the six months ended June 30, 2025 (versus $94.69M and $153.81M in the comparable 2024 periods). R&D expense was $37.88M in Q2 2025 and $69.95M for six months; G&A expense was $10.92M and $21.20M, respectively. Net loss: $43.10M for the quarter and $60.45M for six months (basic net loss per share Q2: $1.04; six months: $1.47).
Corporate developments: first patient dosed in ELEVATE-44-201 and ELEVATE-45-201 initiated; company expects to file for ENTR-601-50 in Q4 2025. Vertex collaboration revenue recognition included a cumulative catch-up adjustment of $12.3M during H1 2025 and the remaining transaction price allocated to unsatisfied obligations was $0.9M at June 30, 2025. The company implemented a ~20% workforce reduction in April 2025 with a related charge of $1.9M. Management states liquidity is sufficient to fund operations into the second quarter of 2027.
Entrada Therapeutics (TRDA) – Form 4 insider transaction summary
Director and 10% owner Dr. Kush Parmar, through two affiliated venture funds, reported open-market sales totaling 125,000 common shares between 27 June and 1 July 2025. The sales were executed at prices ranging from $6.81 to $7.12 per share, generating roughly $0.9-1.2 million in proceeds (exact proceeds depend on final settlement).
- 5AM Ventures V, L.P. sold 92,891 shares across three trades and now owns 3,183,131 shares.
- 5AM Opportunities I, L.P. sold 32,109 shares and now owns 1,100,248 shares.
- The combined position after the transactions is approximately 4.28 million shares, meaning only about 2.8 % of their prior stake was divested.
No derivative securities were involved, and Dr. Parmar continues to disclaim beneficial ownership beyond his pecuniary interest. While insider selling often raises caution among investors, the modest percentage sold and the remaining large holding suggest routine portfolio rebalancing rather than a wholesale exit.
FAQ
What is the current stock price of Entrada Therapeutics (TRDA)?
What is the market cap of Entrada Therapeutics (TRDA)?
